Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 69.08M P/E - EPS this Y 19.20% Ern Qtrly Grth -
Income -113.27M Forward P/E -1.48 EPS next Y 43.40% 50D Avg Chg 112.00%
Sales 9.87M PEG -0.03 EPS past 5Y - 200D Avg Chg -64.00%
Dividend N/A Price/Book 1.92 EPS next 5Y 36.90% 52W High Chg -90.00%
Recommedations 2.20 Quick Ratio 3.30 Shares Outstanding 35.07M 52W Low Chg 190.00%
Insider Own 15.77% ROA -64.45% Shares Float 24.21M Beta 1.87
Inst Own 57.84% ROE -179.55% Shares Shorted/Prior 275.55K/406.08K Price 1.97
Gross Margin - Profit Margin - Avg. Volume 6,821,674 Target Price 11.25
Oper. Margin -957.08% Earnings Date Nov 8 Volume 41,542,091 Change -10.45%
Spero Therapeutics, Inc. News
09/25/22 This Infection-Fighting Biotech Is Recovering Nicely
09/23/22 Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
09/22/22 GSK picks up troubled Spero drug for nearly $300M, takes stake in company
09/22/22 Spero's stock jumps 188% after GSK licenses experimental antibiotic
09/22/22 Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
09/22/22 GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
09/15/22 Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
09/07/22 Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
09/07/22 Spero (SPRO) Up Following Positive FDA Update for UTI Drug
09/07/22 Spero Therapeutics to Present at Upcoming Investor Conference
09/06/22 Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program
09/06/22 Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
09/05/22 Can Spero Therapeutics (NASDAQ:SPRO) Afford To Invest In Growth?
08/25/22 Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
08/10/22 Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
08/10/22 Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
08/09/22 Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
07/06/22 The Women Who Shaped Short-Term Rental History
06/27/22 UPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Chatroom

User Image brallt Posted - 8 minutes ago

$SPRO Not enough volume. Glad I took gains on Friday when looking at this PM action. Not filling me with confidence to jump back in yet.

User Image PlayBookTrades Posted - 15 minutes ago

$LVTX hope you took the $4.20-4.40 dips. $SPRO had the same news and ran HARD.

User Image RealTEAMTrading Posted - 28 minutes ago


User Image Stanekservices17 Posted - 32 minutes ago

$SPRO it went straight to 2.25 at open ! Then shorts tried πŸ˜‚ Gonna be a great day / week here back to 3

User Image PlayBookTrades Posted - 33 minutes ago

$LVTX nice news, same as $SPRO.

User Image heat8842000 Posted - 35 minutes ago

$SPRO creeping up going to be a good day here πŸš€

User Image Horizon_1 Posted - 35 minutes ago

$SPRO who is foolish enough to sell this diamond under 2.00? πŸ™ƒ

User Image StockRunner1 Posted - 42 minutes ago


User Image TimeTaEat Posted - 43 minutes ago

$SPRO 1.29M Premarket volume already

User Image kingkongdeeznuts Posted - 49 minutes ago

$SPRO don't listen to bears lol 1.50 will not happen

User Image DoubleBank Posted - 53 minutes ago

$SPRO looking for 1.50 dip to reload

User Image kingkongdeeznuts Posted - 59 minutes ago

$SPRO if somehow it gets to 1.70ish ill double my positions for an even larger paycheck later

User Image Pilarrubio Posted - 59 minutes ago

$SPRO 🀣🀣🀣🀣🀣🀣🀣🀣

User Image TimeTaEat Posted - 1 hour ago

$SPRO Green is green πŸ‘

User Image kingkongdeeznuts Posted - 1 hour ago

$SPRO fake bids and asks .. go the fuck away with that BS

User Image kingkongdeeznuts Posted - 1 hour ago

$SPRO looks like all we need to do is enlist the same army pumping ISPC!

User Image t51 Posted - 1 hour ago

$SPRO Severely suppressed. Worth a whole lot more. βœ…βœ…πŸš€πŸš€

User Image MarketBeat Posted - 1 hour ago

Spero Therapeutics's PT cut by HC Wainwright to $6.00. https://www.marketbeat.com/r/1822218 $SPRO

User Image kingkongdeeznuts Posted - 1 hour ago

$SPRO todays PM high $2.25 :)

User Image Nicoleneverchase Posted - 1 hour ago

$SPRO HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Lowers Price Target to $6

User Image scottkaitlynr Posted - 1 hour ago

$SPRO the 1y1wk chart on this is bananas

User Image LuiLoeffel Posted - 1 hour ago

$SPRO H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $6.00.

User Image Lalo21 Posted - 1 hour ago

$SPRO f shortes and bears post bullshit , they wake up early lol

User Image Nostradamus696 Posted - 1 hour ago

$SPRO stop posting about ISPC and stupid rubbish meme garbage in this thread. Cross post pump and dumps and you will be reported. $SPRO will be soaring purely on fundamentals not hype

User Image heat8842000 Posted - 1 hour ago

$SPRO sleeping giant that will wake up and start clapping bear cheeks

User Image STCKPRO Posted - 2 hours ago

$SPRO NEW ARTICLE : H.C. Wainwright Reaffirms Their Buy Rating on Spero Therapeutics (SPRO) https://www.stck.pro/news/SPRO/34871007

User Image Newsfilter Posted - 2 hours ago

$SPRO HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics with a Buy and lowers the price target from $7 to $6.

User Image RyanTheeLionn Posted - 2 hours ago

$SPRO don’t let these shorts shake you, prolly going to be a 20-30 cent dump then a 60 cent to 1$ spike immediately after they got you to sell your shares thinking it was going to tank more. Don’t be the one selling for a loss just to see it rip back up later throughout the day

User Image RJMF21 Posted - 2 hours ago

$SPRO If you think it’s a good price at $2 then you’re going to love it at $1.7

User Image Shinobi_Trades Posted - 2 hours ago

$SPRO entire market is red. This will see news lows.

Analyst Ratings
Evercore ISI Group Outperform Sep 23, 22
HC Wainwright & Co. Buy Aug 15, 22
HC Wainwright & Co. Buy May 23, 22
Berenberg Hold May 20, 22
Cantor Fitzgerald Overweight May 17, 22
Cowen & Co. Market Perform May 4, 22
Evercore ISI Group In-Line May 4, 22
HC Wainwright & Co. Buy Apr 18, 22
HC Wainwright & Co. Buy Mar 21, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shukla Sath Chief Financial Offi.. Chief Financial Officer Aug 29 Sell 0.8938 6,017 5,378 56,064 08/30/22
Aquilo Capital Management, LLC 10% Owner 10% Owner Feb 18 Buy 9.2419 14,828 137,039 5,162,963 02/23/22
Aquilo Capital Management, LLC 10% Owner 10% Owner Jan 31 Buy 11.5861 125,000 1,448,262 5,148,135 02/01/22
Aquilo Capital Management, LLC 10% Owner 10% Owner Jan 24 Buy 10.8931 1,599 17,418 5,023,135 01/26/22
Aquilo Capital Management, LLC 10% Owner 10% Owner Jan 18 Buy 12.4147 48,488 601,964 5,021,536 01/20/22
Aquilo Capital Management, LLC 10% Owner 10% Owner Jan 10 Buy 12.9253 8,867 114,609 4,973,048 01/12/22
Mahadevia Ankit CEO and President CEO and President Dec 27 Option 5.9 8,000 47,200 152,036 12/29/21
Mahadevia Ankit CEO and President CEO and President Dec 27 Sell 14.58 8,000 116,640 144,036 12/29/21
Aquilo Capital Management, LLC 10% Owner 10% Owner Sep 15 Buy 18.53 46,366 859,162 4,429,145 09/15/21
Aquilo Capital Management, LLC 10% Owner 10% Owner Aug 27 Buy 16.71 36,939 617,251 4,265,343 08/27/21
- - - Feb 04 Sell 19.05 100,000 1,905,000 3,832,209 02/04/21
- - - Dec 18 Sell 18.72 264,933 4,959,546 3,932,209 12/18/20
- - - Nov 06 Sell 14 174,100 2,437,400 4,323,042 11/06/20
Mahadevia Ankit CEO and President CEO and President Nov 05 Option 5.9 9,507 56,091 73,187 11/05/20
Mahadevia Ankit CEO and President CEO and President Nov 05 Sell 14.35 9,507 136,425 65,817 11/05/20
Mahadevia Ankit CEO and President CEO and President Oct 27 Option 5.9 20 118 65,837 10/27/20
Mahadevia Ankit CEO and President CEO and President Oct 27 Sell 14.25 20 285 65,817 10/27/20
Mahadevia Ankit CEO and President CEO and President Oct 15 Option 5.9 14,472 85,385 65,922 10/15/20
Mahadevia Ankit CEO and President CEO and President Oct 15 Sell 14.27 14,472 206,515 65,817 10/15/20
Mahadevia Ankit CEO and President CEO and President Sep 10 Option 5.9 774 4,567 66,591 09/10/20
Mahadevia Ankit CEO and President CEO and President Sep 10 Sell 14.25 774 11,030 65,817 09/10/20